Welcome to our dedicated page for Pediatrix Medical Group SEC filings (Ticker: MD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pediatrix Medical Group, Inc. (NYSE: MD) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed information about its physician services business focused on women, babies and children. As a Florida corporation with securities registered under Commission File Number 001-12111, Pediatrix uses SEC filings to report operating results, governance changes and significant corporate actions.
On this page, investors can review current and historical filings such as Form 8-K reports that Pediatrix uses to announce quarterly and annual financial results, including net revenue, net income, Adjusted EBITDA and Adjusted EPS. These filings often incorporate earnings press releases by reference and explain how factors like same-unit revenue growth, patient volumes, reimbursement-related trends, payor mix and practice dispositions affect performance. Other 8-K filings describe material events such as the authorization of a share repurchase program or the appointment of new directors to the board.
In addition to event-driven 8-K filings, Pediatrix’s broader SEC reporting (including annual and quarterly reports when available) provides context on its physician services model, focus on neonatology, obstetrics, maternal-fetal medicine and pediatric subspecialties, and the impact of transformational and restructuring related expenses, impairment items and capital structure on its results. These documents also reference non-GAAP measures and include reconciliations to the most directly comparable GAAP measures.
Stock Titan’s SEC filings page for MD is designed to surface these disclosures in one place and to pair them with AI-powered summaries that explain key points in clear language. Users can quickly see what each filing covers, how it relates to Pediatrix’s hospital-based and pediatric subspecialty services, and where items such as share repurchase authorizations, director appointments and portfolio management updates are discussed. This helps investors and researchers interpret complex filings and track how regulatory disclosures reflect the company’s evolving operations.
Pediatrix Medical Group reported stronger profitability for the quarter and year ended December 31, 2025. For the fourth quarter, diluted EPS was $0.40, with Adjusted EPS of $0.50 on net revenue of $493.8 million, down slightly from $502.4 million a year earlier. Same-unit net revenue grew 4.0%, driven by a 6.7% increase from reimbursement-related factors, while same-unit patient service volumes declined 2.7%.
For full-year 2025, net income was $165.4 million versus a net loss of $99.1 million in 2024, translating to diluted EPS of $1.94 compared with a loss of $1.19. Adjusted EBITDA rose to $275.6 million from $224.0 million, and full-year Adjusted EPS increased to $2.04 from $1.51.
Liquidity and leverage also improved. Cash and cash equivalents increased to $375.2 million from $229.9 million, while total debt decreased to $597.3 million from $617.7 million. For 2026, the company projects Adjusted EBITDA between $280 million and $300 million.
Pediatrix Medical Group, Inc. disclosed that its chief executive officer, who also serves as a director, sold 23,000 shares of Pediatrix common stock on December 15, 2025. The shares were sold at a weighted average price of $22.41 per share, with individual sale prices ranging from $22.00 to $22.62.
After completing this transaction, the insider directly beneficially owned 302,805 shares of Pediatrix common stock. The sale was reported as a disposition of non-derivative securities held directly by the reporting person.
Pediatrix Medical Group, Inc. (MD)
After this transaction, the director beneficially owns 59,101 shares of Pediatrix common stock in direct form. The filing notes that detailed trade-by-trade pricing within the reported range is available upon request.
MD filed a Form 144 notice covering a planned sale of common stock. The filing states an intent to sell 10,478 common shares, with an aggregate market value of $240,994, on the NYSE, with an approximate sale date of 11/17/2025. The filing reports that these shares were acquired through stock plan activity from the issuer on several dates in 2021 and 2022. It also notes that total shares of the same class outstanding are 85,877,386. The signer represents that they are not aware of any material adverse, nonpublic information about the issuer’s operations.
Pediatrix Medical Group (MD) reported an insider transaction by a Director. On 11/06/2025, the reporting person sold 10,000 shares of common stock (code S) at a weighted average price of $21.65, with individual trade prices ranging from $21.51 to $21.76.
Following the sale, the reporting person beneficially owned 32,232 shares, held directly. The footnote states the seller will provide full trade-by-trade details within the disclosed price range upon request.
MD filed a Form 144 notice for a proposed sale of 10,000 common shares, reflecting an aggregate market value of $216,150. The filing lists Merrill Lynch as broker, with an approximate sale date of 11/06/2025 on the NYSE.
The shares were acquired via stock plan activity from the issuer in two tranches: 1,480 shares on 05/12/2023 and 8,520 shares on 05/11/2024.
Pediatrix Medical Group (MD) reported stronger Q3 results. Net revenue was $492.9 million versus $511.2 million a year ago, reflecting practice dispositions partly offset by growth at ongoing sites. Net income rose to $71.7 million from $19.4 million, and diluted EPS increased to $0.84 from $0.23. Adjusted EBITDA improved to $87.3 million from $60.2 million as operating margin expanded to 13.8%.
Same‑unit net revenue increased 8.0%, driven by better collections, higher patient acuity in neonatology, higher hospital administrative fees, and a slightly favorable payor mix. Transformational and restructuring expenses declined to $6.0 million. Non‑operating results benefited from a $20.9 million net gain on investments in divested businesses.
For the nine months, revenue was $1.42 billion and net income was $131.7 million. Cash and cash equivalents rose to $340.1 million, aided by lower days sales outstanding of 43.1 days. The company acquired women’s and children’s practices for $19.2 million and repurchased 1.2 million shares for $20.9 million under a new $250 million authorization. Debt included $400.0 million of 2030 notes and $201.6 million on the Term A Loan with $450.0 million revolver availability.
Pediatrix Medical Group, Inc. filed an 8‑K announcing it furnished a press release with results for the three and nine months ended September 30, 2025. The information was provided under Item 2.02 and, along with Exhibit 99.1, is furnished and not deemed filed. The company’s common stock trades on the NYSE under the symbol MD.
Pediatrix Medical Group insider transfer disclosure. Thomas McEachin, a director, reported transfers of common stock on August 19 and August 20, 2025. The filings show 54,021 shares were transferred on August 19, 2025, and 625 shares on August 20, 2025, each reported as dispositions at $0. After the transactions the report lists 11,427 shares held directly and 54,646 shares held indirectly by the Thomas A. McEachin Living Trust dated April 17, 2025. The Form 4 was executed by an attorney-in-fact and signed on August 21, 2025. The reporting person and spouse are identified as trustees and beneficiaries of the trust that holds the reported securities.